.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
AstraZeneca
US Department of Justice
Chinese Patent Office
McKinsey
Accenture
Covington
Baxter
Argus Health
Julphar

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,601,727

« Back to Dashboard

Details for Patent: 7,601,727

Title:Pyrrolo[2,3-d]pyrimidine compounds
Abstract: A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s): Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee: Pfizer, Inc. (New York, NY)
Filing Date:Jul 27, 2007
Application Number:11/829,217
Claims:1. A method for treating asthma comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal.

2. The method of claim 1 comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal.

3. The method of claim 2 wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts.

4. The method of claim 1 wherein the therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or pharmaceutically acceptable salt thereof is administered orally.

5. The method of claim 1 wherein the mammal is a human.

6. The method of claim 1 further comprising administering one or more additional agents which modulate a mammalian immune system or antiinflamatory agents to the mammal.

7. A method for treating psoriasis comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal.

8. The method of claim 7 comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal.

9. The method of claim 8 wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts.

10. The method of claim 7 wherein the therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or pharmaceutically acceptable salt thereof is administered orally.

11. The method of claim 7 comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal.

12. The method of claim 7 further comprising administering one or more additional agents which modulate a mammalian immune system or antiinflamatory agents to the mammal.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Johnson and Johnson
Chinese Patent Office
Queensland Health
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
US Department of Justice
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot